Challenge of phosphorus control in hemodialysis patients: A problem of adherence?

Journal of Nephrology

Volumn 23, Issue 5, 2010, Pages 525-534

  Arenas, María Dolores ^a   Malek, Tamara ^a   Gil, María Teresa ^a   Moledous, Analía ^a   Alvarez Ude, Fernando ^b   Reig Ferrer, Abilio ^c  

^a HOSPITAL PERPETUO SOCORRO   (Spain)

^b HOSPITAL GENERAL DE SEGOVIA   (Spain)

^c UNIVERSITY OF ALICANTE   (Spain)

Author keywords

Adherence; Compliance; Hypotensive agents; Phosphate binders; Phosphorus

Indexed keywords

ANTIHYPERTENSIVE AGENT; PHOSPHATE BINDING AGENT; PHOSPHORUS; POTASSIUM;

AGE; AGED; ARTICLE; BLOOD PRESSURE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; QUESTIONNAIRE;

ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHOSPHORUS; QUESTIONNAIRES; RENAL DIALYSIS;

EID: 78049237517     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. DiMatteo MR, DiNicola DD. Achieving patient compliance: the psychology of the medical practitioner's role. New York: Pergamon Press; 1982.
2. De Geest S, Sabaté E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs. 2003;2:323. (Pubitemid 37518223)
3. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002;288:2868-2879.
4. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
5. Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44(Suppl 2):34-38.
6. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67:1179-1187.
7. Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, Rodriguez M, Aljama P. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis. 2005;46:68-77.
8. Arenas MD, Alvarez-Ude F, Gil MT, et al. Application of NKFK/DOQI clinical practice guidelines for bone metabolism and disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units. Nephrol Dial Transplant. 2006;21:1663-1668.
9. Wei M, Taskapan H, Esbaei K, Jassal SV, Bargman JM, Oreopoulos DG. K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them? Int Urol Nephrol. 2006;38:739-743.
10. Lorenzo V, Martín-Malo A, Pérez-García R, et al. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study. Nephrol Dial Transplant. 2006;21:459-465.
11. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 2003;42:96-107.
12. Slatopolsky EA, Burke SK, Dillon MA; and the Renagel study group. Renagel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int. 1999;55:299-307.
13. Sechet A, Hardy P, Hottelart C, et al. Role of calcium carbonate administration timing in relation to food intake on its efficiency in controlling hyperphosphatemia in patients on maintenance dialysis. Artif Organs. 1998;22:564-568.
14. Arenas MD, Malek T, Gil MT, Moledous A, Núñez C, Álvarez-Ude F. Use of aluminum-based phosphate-chelators in hemodialysis in the era of ultrapure water. Nefrologia. 2008;28:168-173.
15. Sprague SM. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin. 2007;23:3167-3175.
16. Karamanidou C, Clatworthy J, Weinman J, Horne R. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol. 2008;9:2.
17. Ceballos M, López-Revuelta K, Saracho R, et al. [Dialysis and transplant patients Registry of the Spanish Society of Nephrology] [article in Spanish]. Nefrologia. 2005;25:121-124, 126-129.
18. White CA, Jaffey J, Magner P. Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients. Kidney Int. 2007;71:312-317.
19. Knobel H, Alonso J, Casado JL, et al; GEEMA Study Group. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA study. AIDS. 2002;16:605-613.
20. National Kidney Foundation. NKF-K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(Suppl 3):S1-S201.
21. Leggat JE Jr, Orzol SM, Hulbert-Shearon TE, et al. Noncompliance in hemodialysis: predictors and survival analysis. Am J Kidney Dis. 1998;32:139-145.
22. Denhaerynck K, Manhaeve D, Dobbels F, Garzoni D, Nolte C, De Geest S. Prevalence and consequences of nonadherence to hemodialysis regimens. AJCC American Journal of Critical Care. 2007;16:222-235.
23. Hemmelgarn BR, Manns BJ, Quan H, Ghali WA. Adapting the Charlson Comorbidity Index for use in patients with ESRD. Am J Kidney Dis. 2003;42:125-132.
24. Arenas MD, Alvarez-Ude F, Angoso M, et al. [Functional dependency evaluation of hemodialysis patients: a multicentric study] [article in Spanish]. Nefrologia. 2006;26:600-608.
25. Knobel H, Codina C, MiróJM, et al. Recomendaciones GESIDA/SEFH/PNS para mejorar la adherencia al tratamiento antirretroviral. Enferm Infecc Microbiol Clin. 2000;18:27-39.
26. Unruh ML, Evans IV, Fink NE, Powe NR, Meyer KB; Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Skipped treatments, markers of nutritional nonadherence, and survival among incident hemodialysis patients. Am J Kidney Dis. 2005;46:1107-1116.
27. Morales López C, Burrowes JD, Gizis F, Brommage D. Dietary adherence in Hispanic patients receiving hemodialysis. J Ren Nutr. 2007;17:138-147.
28. Kara B, Caglar K, Kilic S. Nonadherence with diet and fluid restrictions and perceived social support in patients receiving hemodialysis. J Nurs Scholarsh. 2007;39:243-248.
29. Kaveh K, Kimmel PL. Compliance in hemodialysis patients: multidimensional measurements in search of a gold standard. Am J Kidney Dis. 2001;37:244-266.
30. Tentori F, Hunt WC, Rohrscheib M, et al. Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization? J Am Soc Nephrol. 2007;18:2377-2384.
31. Murri R, Antinori A, Ammassari A, et al; AdICoNA Study Group. Physician estimates of adherence and the patient-physician relationship as a setting to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:S158-S162.
32. Miller LG, Liu H, Hays RD, et al. How well do clinicians estimate patients' adherence to combination antiretroviral therapy? J Gen Intern Med. 2002;17:1-11.
33. Elliott RA, Barber N, Horne R. Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence. Ann Pharmacother. 2005;39:508-515. Published online January 18, 2005.
34. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4:1089-1096.
35. Arenas MD, Álvarez-Ude F, Moledous A, et al. Can we improve our results in hemodialysis? Setting quality objectives, feedback, and benchmarking. Nefrologia. 2008;28:397-406.
36. Horne R. Compliance, adherence and concordance. In: Taylor K, Harding G, eds. Pharmacy practice. London: Taylor and Francis; 2001:165-184.
37. Akman B, Uyar M, Afsar B, Sezer S, Ozdemir FN, Haberal M. Adherence, depression and quality of life in patients on a renal transplantation waiting list. Transpl Int. 2007;20:682-687.
38. Arenas MD, Álvarez-Ude F, Reig-Ferrer A, et al. Emotional distress (anxiety and/or depression) and health related quality of life in patients on hemodialysis: the clinical value of Coop- Wonca charts. J Nephrol. 2007;20:304-310.
39. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-1310.
40. Nieuwkerk PT, Sprangers MAG, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med. 2001;161:1962-1968.
41. Goff SL, Mazor KM, Meterko V, Dodd K, Sabin J. Patients' beliefs and preferences regarding doctors' medication recommendations. J Gen Intern Med. 2008;23:236-241.